Abiraterone monitoring was linked to lower cortisol, with uncertain implications
A retrospective prostate cancer study found lower cortisol, while the primary threshold outcome and results after monitoring-guided interventions remained statistically inconclusive.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Patients whose abiraterone blood levels were monitored had lower cortisol than a historical standard-care group. However, the difference in reaching the study's cortisol threshold was not statistically significant. Changes after monitoring-guided interventions also failed to show a clear improvement in that endpoint. These biomarker results do not establish better cancer outcomes.
This abstract-based comparison used historical controls rather than random allocation. It cannot establish that monitoring caused the cortisol difference, and the abstract provides no cancer-control or survival results.
What researchers found
Patients meeting the cortisol-defined inhibition threshold
Monitoring versus historical standard care; cortisol <6.18 nmol/L defined adequate enzyme inhibition. Timing not reported; difference not statistically significant.
What cortisol represented
The researchers used cortisol in blood as an indirect indicator of whether abiraterone inhibited its intended enzyme target. Meeting the study's threshold was the main outcome, distinct from measuring tumor response or survival.
Intervention results were uncertain
Among patients with measurements before and after an intervention, adequate drug concentrations were commonly reached. Yet the cortisol-defined inhibition outcome did not improve significantly, leaving uncertainty about whether increasing drug exposure changed this biomarker.
The original publication
Impact of Abiraterone Therapeutic Drug Monitoring on Cortisol as a Surrogate Biomarker of CYP17 Inhibition in Metastatic Prostate Cancer Treatment.
van Merendonk LN, van der Kleij MBA, Bergman AM et al.
Ther Drug Monit · 2026
- PubMed ID
- 41666353
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.